Trust Point Inc. acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 451 shares of the company’s stock, valued at approximately $228,000.
A number of other institutional investors have also modified their holdings of the company. Riverview Trust Co purchased a new stake in IDEXX Laboratories during the first quarter worth approximately $26,000. Crewe Advisors LLC acquired a new stake in IDEXX Laboratories during the 1st quarter valued at $26,000. Ridgewood Investments LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter worth $27,000. Institutional & Family Asset Management LLC acquired a new position in IDEXX Laboratories in the 2nd quarter worth $28,000. Finally, Strategic Investment Solutions Inc. IL purchased a new position in IDEXX Laboratories in the 2nd quarter valued at about $36,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Stock Performance
IDXX stock opened at $457.74 on Friday. The stock’s fifty day moving average is $487.50 and its two-hundred day moving average is $491.55. The stock has a market capitalization of $37.80 billion, a price-to-earnings ratio of 44.31, a PEG ratio of 4.14 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39.
Analysts Set New Price Targets
A number of analysts have recently issued reports on IDXX shares. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Piper Sandler cut their target price on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, BTIG Research began coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective on the stock. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $574.13.
View Our Latest Stock Analysis on IDEXX Laboratories
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
- Five stocks we like better than IDEXX Laboratories
- Insider Buying Explained: What Investors Need to Know
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Find Undervalued Stocks
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- MarketBeat Week in Review – 10/14 – 10/18
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.